1.96
price down icon0.51%   -0.01
after-market After Hours: 1.93 -0.03 -1.53%
loading
Can-Fite Biopharma Ltd ADR stock is traded at $1.96, with a volume of 98,943. It is down -0.51% in the last 24 hours and down -30.50% over the past month. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$1.97
Open:
$2
24h Volume:
98,943
Relative Volume:
1.01
Market Cap:
$11.95M
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.8332
EPS:
-2.3523
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-30.50%
6M Performance:
-17.65%
1Y Performance:
-7.03%
1-Day Range:
Value
$1.90
$2.02
1-Week Range:
Value
$1.90
$2.11
52-Week Range:
Value
$1.8661
$4.69

Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile

Name
Name
Can-Fite Biopharma Ltd ADR
Name
Phone
972 3 924 1114
Name
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Name
Employee
7
Name
Twitter
@CanFitePharma
Name
Next Earnings Date
2024-11-28
Name
Latest SEC Filings
Name
CANF's Discussions on Twitter

Compare CANF with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CANF 1.96 11.95M 743.00K -7.63M 0 -2.3523
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-11-17 Initiated Maxim Group Buy
Oct-19-16 Resumed ROTH Capital Buy
Aug-29-16 Resumed Rodman & Renshaw Buy
Nov-30-15 Reiterated H.C. Wainwright Buy
Mar-31-15 Reiterated H.C. Wainwright Buy
Mar-30-15 Downgrade ROTH Capital Buy → Neutral
Dec-29-14 Reiterated ROTH Capital Buy
Nov-18-14 Initiated H.C. Wainwright Buy
View All

Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News

pulisher
Nov 11, 2024

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewswire Inc.

Nov 11, 2024
pulisher
Nov 04, 2024

Can-Fite secures Australian patent for obesity treatment - Investing.com

Nov 04, 2024
pulisher
Oct 18, 2024

Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India

Oct 18, 2024
pulisher
Sep 25, 2024

Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News

Sep 24, 2024
pulisher
Sep 02, 2024

Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News

Sep 02, 2024
pulisher
Aug 26, 2024

List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel

Aug 26, 2024
pulisher
Aug 23, 2024

Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com

Aug 23, 2024
pulisher
Jul 17, 2024

Can-Fite BioPharma shares upgraded by EF Hutton to Buy on pipeline drugs - Investing.com

Jul 17, 2024
pulisher
Jun 28, 2024

GitLab stock maintains buy rating on new release By Investing.com - Investing.com

Jun 28, 2024
pulisher
Jun 28, 2024

Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo New Zealand News

Jun 28, 2024
pulisher
Jun 28, 2024

Canine arthritis treatment shows promise in clinical study - Investing.com India

Jun 28, 2024
pulisher
Jun 25, 2024

Can-Fite reveals adiponectin role in cancer treatment By Investing.com - Investing.com

Jun 25, 2024
pulisher
Jun 19, 2024

Was Can-Fite Biopharma Ltd ADR (CANF)'s session last reading good? – US Post News - US Post News

Jun 19, 2024
pulisher
Jun 05, 2024

Can-Fite's Namodenoson gains FDA Fast Track for liver cancer - Investing.com India

Jun 05, 2024
pulisher
Jun 05, 2024

Can-Fite's Namodenoson gains FDA Fast Track for liver cancer By Investing.com - Investing.com

Jun 05, 2024
pulisher
Apr 15, 2024

Can-Fite's Namodenoson advances in Phase III liver cancer trial By Investing.com - Investing.com

Apr 15, 2024
pulisher
Apr 03, 2024

Can-Fite BioPharma seeks FDA nod for NASH drug trial By Investing.com - Investing.com

Apr 03, 2024
pulisher
Jan 05, 2024

ANVS Stock Quote Price and Forecast - CNN

Jan 05, 2024
pulisher
Nov 21, 2023

symbol__ Stock Quote Price and Forecast - CNN

Nov 21, 2023
pulisher
Jul 12, 2023

Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire

Jul 12, 2023
pulisher
Dec 30, 2022

Can-Fite Announces ADS Ratio Change - Business Wire

Dec 30, 2022
pulisher
Nov 10, 2022

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates - Nasdaq

Nov 10, 2022
pulisher
Oct 19, 2022

Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici

Oct 19, 2022
pulisher
Mar 16, 2021

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire

Mar 16, 2021
pulisher
Feb 25, 2021

Best Penny Stocks Today | Penny Stocks to Buy Now -TipRanksTipRanks.com - TipRanks

Feb 25, 2021
pulisher
Oct 15, 2020

The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Trea - Benzinga

Oct 15, 2020
pulisher
Sep 16, 2020

Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat

Sep 16, 2020
pulisher
Mar 03, 2020

The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And Mo - Benzinga

Mar 03, 2020
pulisher
Aug 24, 2019

10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance

Aug 24, 2019
pulisher
Aug 08, 2019

The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax OfferingiShares B - Benzinga

Aug 08, 2019
pulisher
May 24, 2019

Secondary Offerings Put A Pause On May's MomentumMynd.ai (AMEX:MYND), Can Fite Biofarma (AMEX:CANF) - Benzinga

May 24, 2019
pulisher
Feb 05, 2018

28 Stocks Moving In Monday's Pre-Market Session - Benzinga

Feb 05, 2018
pulisher
Apr 25, 2017

20 Biggest Mid-Day Gainers For TuesdayAlcoa (NYSE:AA), Biogen (NASDAQ:BIIB) - Benzinga

Apr 25, 2017
pulisher
Aug 02, 2016

Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha

Aug 02, 2016
pulisher
Oct 05, 2015

Propanc Health Group Corp : This Company Could Be the Next CETX or CANF - Marketscreener.com

Oct 05, 2015
pulisher
Sep 17, 2015

Morning Market GainersCan Fite Biofarma (AMEX:CANF) - Benzinga

Sep 17, 2015
pulisher
Oct 04, 2012

Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC

Oct 04, 2012

Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):